Evidence map›Paper›PMID 21735044›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2011

Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension.

Georg Hansmann, Brian D Plouffe, Adam Hatch, Alexander von Gise, Hannes Sallmon, Roham T Zamanian, Shashi K Murthy

Open access · greenAbstract readValidation Study
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 52 citations in OpenAlex.

  1. Stem cell therapy in pulmonary hypertension: current practice and future opportunities.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  2. Organ Chips and Visualization of Biological Systems.Advances in experimental medicine and biology · 2023
    Article
  3. Review
  4. Therapeutic Potential of Endothelial Progenitor Cells in Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021
    Review
  5. Review
  6. Article
  7. Review
  8. Understanding angiogenesis during aging: opportunities for discoveries and new models.Journal of applied physiology (Bethesda, Md. : 1985) · 2018
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Fundamentals and application of magnetic particles in cell isolation and enrichment: a review.Reports on progress in physics. Physical Society (Great Britain) · 2015
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Georg HansmannDepartment of Cardiology, Children's Hospital Boston, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. georg.hansmann@gmail.com
Brian D Plouffe
Adam Hatch
Alexander von Gise
Hannes Sallmon
Roham T Zamanian
Shashi K Murthy
Northeastern University · USBoston Children's Hospital · USHarvard University · USStanford University · US

Funding

Microfluidic Cell Separation for Tissue Engineering and Regenerative MedicineR01EB009327 · NIBIB · NORTHEASTERN UNIVERSITY · PI MURTHY, SHASHI · 2010 to 2012
$1.8M
NIBIB NIH HHS R01 EB009327
6 · The paper itself

Abstract

The number of circulating endothelial progenitor cells (EPCs) inversely correlates with cardiovascular risk and clinical outcome, and thus has been proposed as a valuable biomarker for risk assessment, disease progression, and response to therapy. However, current strategies for isolation of these rare cells are limited to complex, laborious approaches. The goal of this study was the design and validation of a disposable microfluidic platform capable of selectively capturing and enumerating EPCs directly from human whole blood in healthy and diseased subjects, eliminating sample preprocessing. We then applied the "EPC capture chip" clinically and determined EPC numbers in blood from patients with pulmonary arterial hypertension (PAH). Blood was collected in tubes and injected into polymeric microfluidic chips containing microcolumns pre-coated with anti-CD34 antibody. Captured cells were immunofluorescently stained for the expression of stem and endothelial antigens, identified and counted. The EPC capture chip was validated with conventional flow cytometry counts (r = 0.83). The inter- and intra-day reliability of the microfluidic devices was confirmed at different time points in triplicates over 1-5 months. In a cohort of 43 patients with three forms of PAH (idiopathic/heritable, drug-induced, and connective tissue disease), EPC numbers are ≈50% lower in PAH subjects vs. matched controls and inversely related to two potential disease modifiers: body mass index and postmenopausal status. The EPC capture chip (5 × 30 × 0.05 mm(3)) requires only 200 μL of human blood and has the strong potential to serve as a rapid bedside test for the screening and monitoring of patients with PAH and other proliferative cardiovascular, pulmonary, malignant, and neurodegenerative diseases.

Indexed as

AdultAgedAgingBody Mass IndexCase-Control StudiesCell CountCell SeparationEndothelial CellsEquipment DesignFamilial Primary Pulmonary HypertensionFemaleHumansHypertension, PulmonaryMaleMicrofluidic Analytical TechniquesMiddle Aged

Identifiers

PMID21735044
PMCPMC3306233
OpenAlexW2123475727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.